Merck sends BACE advanced raiding party into corpse-littered Alzheimer's landscape
This article was originally published in Scrip
Executive Summary
Merck & Co is to take its BACE1 inhibitor MK-8931 into Phase II/III in Alzheimer's disease just days after yet another candidate, Bristol-Myers Squibb's avagacestat, was discontinued.